Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

被引:29
|
作者
McCaughan, Georgia J. B. [3 ]
Fulham, Michael J. [1 ,3 ]
Mahar, Annabelle [3 ]
Soper, Judy [3 ,4 ]
Hong, Angela M. [1 ,2 ]
Stalley, Paul D. [3 ]
Tattersall, Martin H. N. [1 ,2 ]
Bhadri, Vivek A. [1 ,2 ]
机构
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[2] Chris OBrien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia
[4] Specialist Magnet Resonance Imaging, Newton, NSW, Australia
来源
关键词
Ewing sarcoma; Immunotherapy; Anti-programmed cell death-1 antibody; Case report; GENOMIC INSTABILITY; CANCER; SURVIVAL; EXPERIENCE; NIVOLUMAB; ANTIBODY; THERAPY; REPAIR; FAMILY; TUMORS;
D O I
10.1186/s13045-016-0278-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. Case presentation: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. Conclusions: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu Qiang
    Li Chun-Sheng
    中华医学杂志英文版, 2017, 130 (08) : 986 - 992
  • [22] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu, Qiang
    Li, Chun-Sheng
    CHINESE MEDICAL JOURNAL, 2017, 130 (08) : 986 - 992
  • [23] MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
    Zanella, Anais
    Doussot, Alexandre
    Puzenat, Eve
    Aubin, Francois
    Nardin, Charlee
    MELANOMA RESEARCH, 2020, 30 (06) : 606 - 607
  • [24] Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy
    Salem, Mohamed L.
    El-Badawy, Ahmed
    WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (23) : 2449 - 2458
  • [25] Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
    Yang, Guozhen
    Su, Xiaodong
    Yang, Hong
    Luo, Guangyu
    Gao, Chan
    Zheng, Yating
    Xie, Wenzhuan
    Huang, Mengli
    Bei, Ting
    Bai, Yuezong
    Wang, Zhiqiang
    Cai, Peiqiang
    He, Haoqiang
    Xiang, Jin
    Cai, Muyan
    Zhang, Yijun
    Qu, Chunhua
    Fu, Jianhua
    Liu, Qianwen
    Hu, Yi
    Zhong, Jiudi
    Huang, Yuanheng
    Guo, Qiyu
    Zhang, Xu
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (15)
  • [26] Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy
    Mohamed L Salem
    Ahmed El-Badawy
    World Journal of Hepatology, 2015, 7 (23) : 2449 - 2458
  • [27] Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
    Versteven, Maarten
    Van den Bergh, Johan M. J.
    Marcq, Elly
    Smits, Evelien L. J.
    Van Tendeloo, Viggo F. I.
    Hobo, Willemijn
    Lion, Eva
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [28] Programmed death-1 blockade in mismatch repair deficient colorectal cancer.
    Le, Dung T.
    Uram, Jennifer N.
    Wang, Hao
    Bartlett, Bjarne
    Kemberling, Holly
    Eyring, Aleksandra
    Azad, Nilofer Saba
    Laheru, Dan
    Donehower, Ross C.
    Crocenzi, Todd S.
    Goldberg, Richard M.
    Fisher, George A.
    Lee, James J.
    Greten, Tim F.
    Koshiji, Minori
    Kang, SoonMo Peter
    Anders, Robert A.
    Eshleman, James R.
    Vogelstein, Bert
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
    Brown, JA
    Dorfman, DM
    Ma, FR
    Sullivan, EL
    Munoz, O
    Wood, CR
    Greenfield, EA
    Freeman, GJ
    JOURNAL OF IMMUNOLOGY, 2003, 170 (03): : 1257 - 1266
  • [30] Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action
    Zhang, Ni
    Tu, Jingyao
    Wang, Xue
    Chu, Qian
    IMMUNOTHERAPY, 2019, 11 (05) : 429 - 441